Med BioGene Shareholders Approve Commercialization Deal with Precision Therapeutics

Med BioGene's shareholders have approved the deal, which gives Precision rights to commercialize Med BioGene's gene expression-based test for early stage non-small-cell lung cancer.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.